Key facts
- Rose Lab’s last known valuation is $36.0M (Sep 2025).
- It has raised $7.2M; the latest was Later Stage VC ($7.2M) in Sep 2025.
- Notable investors include Tech Incubator Program for Startup, Korea Investment Partners, Shinhan Capital, Daedeok Venture Partners, GS Ventures (Korea) — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Rose Lab
- ·The full record, as it builds
Funding rounds
No funding rounds for Rose Lab are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rose Lab
Developer of a nanosized filler designed to facilitate tissue restoration for facial plastic surgery. The company provides polymer-based restorative materials for living tissues and develops various medical technologies, such as polymer materials and cell therapy matrix development, which help to produce collagen in the body, enabling clients to improve skin aging.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2016
- Employees
- 24
- Website
- roselab.co.kr/
- Ownership
- Privately Held (backing)
Rose Lab doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rose Lab shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rose Lab in its N-PORT filings yet. We sweep new filings monthly.